###begin article-title 0
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Reduced transcription of TCOF1 in adult cells of Treacher Collins syndrome patients
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 133 139 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 446 452 446 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 502 507 <span type="species:ncbi:9606">human</span>
Treacher Collins syndrome (TCS) is an autosomal dominant craniofacial disorder caused by frameshift deletions or duplications in the TCOF1 gene. These mutations cause premature termination codons, which are predicted to lead to mRNA degradation by nonsense mediated mRNA decay (NMD). Haploinsufficiency of the gene product (treacle) during embryonic development is the proposed molecular mechanism underlying TCS. However, it is still unknown if TCOF1 expression levels are decreased in post-embryonic human cells.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
We have estimated TCOF1 transcript levels through real time PCR in mRNA obtained from leucocytes and mesenchymal cells of TCS patients (n = 23) and controls (n = 18). Mutational screening and analysis of NMD were performed by direct sequencing of gDNA and cDNA, respectively.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 217 225 217 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt; 0.05</italic>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
All the 23 patients had typical clinical features of the syndrome and pathogenic mutations were detected in 19 of them. We demonstrated that the expression level of TCOF1 is 18-31% lower in patients than in controls (p < 0.05), even if we exclude the patients in whom we did not detect the pathogenic mutation. We also observed that the mutant allele is usually less abundant than the wild type one in mesenchymal cells.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 406 412 406 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 450 456 450 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 573 581 <span type="species:ncbi:9606">patients</span>
###xml 724 732 <span type="species:ncbi:9606">patients</span>
This is the first study to report decreased expression levels of TCOF1 in TCS adult human cells, but it is still unknown if this finding is associated to any phenotype in adulthood. In addition, as we demonstrated that alleles harboring the pathogenic mutations have lower expression, we herein corroborate the current hypothesis of NMD of the mutant transcript as the explanation for diminished levels of TCOF1 expression. Further, considering that TCOF1 deficiency in adult cells could be associated to pathologic clinical findings, it will be important to verify if TCS patients have an impairment in adult stem cell properties, as this can reduce the efficiency of plastic surgery results during rehabilitation of these patients.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 419 420 419 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 679 680 679 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
Treacher Collins syndrome (TCS; OMIM 154500) is a rare autosomal dominant craniofacial disorder (1:50.000) characterized by bilateral and symmetrical malformations, which frequently includes hypoplasia of the mandible and zygomatic complex, down-slanting palpebral fissures, coloboma of the lower eyelid and absence of eyelashes medial to this defect, external and middle ear malformation, and conductive hearing loss [1]. The penetrance is considered to be complete, but there is a high inter and intra-familial phenotypic variation, ranging from cases with perinatal death due to airway obstruction by severe orofacial malformations to those that are not clinically diagnosed [2].
###end p 10
###begin p 11
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 299 305 299 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 611 612 611 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 703 708 703 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1</italic>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
###xml 659 664 <span type="species:ncbi:9606">human</span>
###xml 668 673 <span type="species:ncbi:10090">mouse</span>
In most of the cases the disorder is caused by frameshift deletions or duplications of 1-41 bp in TCOF1 coding region which cause premature termination codons (PTC). Except for a recurring 5 bp deletion in exon 24 that is responsible for 17% of the cases, mutations are usually family-specific [3]. TCOF1 gene product is a nucleolar protein (treacle) involved in rRNA transcription and in pre-rRNA post-transcriptional modification [4]. Truncated proteins are not detected in TCS patients' fibroblasts and lymphocytes, suggesting that mRNA bearing PTCs are being degraded by nonsense mediated mRNA decay (NMD) [5]; however, NMD has never been demonstrated in human or mouse cells with null mutations in TCOF1.
###end p 11
###begin p 12
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
No genotype-phenotype correlation has been observed in TCS and there is also no evidence of association between the disease severity and parental origin or type of the pathogenic mutation, male or female sex, sporadic or familial cases [5-9].
###end p 12
###begin p 13
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 187 195 187 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In situ </italic>
###xml 224 230 224 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tcof1 </italic>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 405 411 405 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tcof1 </italic>
###xml 485 494 485 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tcof1+/- </italic>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 813 814 813 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 629 637 <span type="species:ncbi:9606">patients</span>
TCOF1 is expressed in various adult and embryonic tissues and haploinsufficiency of treacle during embryonic development has been proposed as the molecular mechanism underlying TCS [10]. In situ hybridization studies of the Tcof1 orthologue demonstrated that there is a peak of expression of the gene in E8.5-9.5 mice embryos, especially in the first and second pharyngeal arches [11]. Critical dosage of Tcof1 for appropriate craniofacial development has been further demonstrated in Tcof1+/- mice [12,13]. Interestingly, a previous study observed that cellular amount of treacle in fibroblasts and lymphocytes derived from TCS patients was indistinguishable from that of control individuals, and the authors suggested that a dosage compensation mechanism could occur in adulthood to compensate the null allele [5]. However, until the present, these findings have not been confirmed.
###end p 13
###begin p 14
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 448 454 448 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 530 535 <span type="species:ncbi:9606">human</span>
The relevance of TCOF1 happloinsufficiency during adult life is still rarely studied: it can predispose to age related macular degeneration [14] and explain the absence of long-term stable results in mandibular distraction for facial reconstruction [15-17]. These findings might imply that TCOF1 adult stem cells present a decreased regenerative capacity in comparison to wild-type cells. We have therefore conducted the present study to verify if TCOF1 expression is altered in adult TCS cells as well as to identify a source of human tissue suitable for functional studies of treacle in adulthood.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 16
###begin p 17
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 579 587 <span type="species:ncbi:9606">patients</span>
We studied peripheral blood samples from 20 TCS patients (TCS1 to 20, ranging from 3 to 41 years old) referred to our center for genetic counseling and 12 controls (ranging from 20 to 50 years old). We also obtained tissue samples from TCS16, from three other patients (TCS21 to 23), and from six controls submitted to reconstructive plastic surgery at University of Sao Paulo Medical School. The study was approved by the ethical committee of our Institution and informed consent was obtained from both patients and control subjects or from their legal tutors. In total, 23 TCS patients were studied.
###end p 17
###begin title 18
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Isolation of cells from periosteum of TCS patients
###end title 18
###begin p 19
###xml 74 82 <span type="species:ncbi:9606">patients</span>
During corrective surgery, overlying periosteum from the face of four TCS patients (two males and two females aged from 6 to 29 years) was meticulously dissected away from surrounding tissues to isolate intact periosteal flaps. Control periosteum was obtained using the same procedure from facial region of six subjects (four males and two females aged from 11 months to 20 years) with no evidence of bone disease during corrective surgery.
###end p 19
###begin p 20
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 726 728 720 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sup>
###xml 743 745 737 739 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
###xml 535 541 <span type="species:ncbi:9913">bovine</span>
Mesenchymal cells were isolated as described by previous reports from our group [18,19]. The periosteal flaps were thoroughly washed with sterile phosphate-buffered saline (PBS) supplemented with 4% antibiotics (100 units/mL penicillin and 100 mg/mL streptomycin; Invitrogen), and digested with trypsin solution (TrypLe; Invitrogen) for 1 h at 37degreesC. Once digested, the tissue was transferred with minimal dissection into 35 mm Petri dishes (Corning, NY) containing Dulbecco's modified Eagle's medium (DMEM; GIBCO) with 10% fetal bovine serum (FBS; GIBCO), 100 units/mL penicillin, and 100 mg/mL streptomycin (Invitrogen). After two weeks, cells were washed with PBS, then dissociated in trypsin solution and seeded at 104 cells per 25 cm2 for the first passage. For expansion, cells were cultured in monolayer in growth medium at 37degreesC in a humidified atmosphere of 5% CO2. The medium was replaced every 3 days. In order to prevent cell differentiation, cultures were maintained semiconfiuent and subcultured every 4-5 days with daily medium changes.
###end p 20
###begin title 21
Flow cytometry
###end title 21
###begin p 22
###xml 487 489 475 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sup>
###xml 126 131 <span type="species:ncbi:9606">human</span>
###xml 346 351 <span type="species:ncbi:10090">mouse</span>
###xml 375 380 <span type="species:ncbi:120290">Guava</span>
###xml 550 555 <span type="species:ncbi:120290">Guava</span>
###xml 673 678 <span type="species:ncbi:10090">mouse</span>
###xml 743 748 <span type="species:ncbi:120290">Guava</span>
###xml 771 776 <span type="species:ncbi:120290">Guava</span>
Cells were harvested with TrypLe (Invitrogen), washed with PBS, and incubated at 4degreesC for 30 min with the following anti-human antibodies: CD29-PE CY5, CD90 (Thy-1), CD45-FITC, CD73, CD105, CD117, CD 31-PE (Becton Dickinson) and SH3 (Case Western Reserve University). After the wash, unconjugated primary antibodies were incubated with anti-mouse-PE secondary antibody (Guava Technologies) for additional 15 min at 4degreesC. Finally, the cell suspension was washed with PBS, and 104 labeled cells were acquired with an EasyCyte flow cytometer (Guava Technologies). Control samples were incubated with PBS instead of primary antibody, followed by incubation with anti-mouse-PE secondary antibody. All the generated plots were analyzed in Guava ExpressPlus software (Guava Technologies).
###end p 22
###begin title 23
DNA and RNA isolation and cDNA synthesis
###end title 23
###begin p 24
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 263 267 263 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174; </sup>
###xml 268 277 266 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gibco BRL</italic>
###xml 293 299 291 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DNAse </italic>
###xml 300 307 298 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Promega</italic>
###xml 354 391 352 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Superscript II Reverse Transcriptase </italic>
###xml 392 401 390 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gibco BRL</italic>
###xml 456 462 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DNAse </italic>
###xml 528 533 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
Genomic DNA from peripheral blood samples was obtained according to reference [20] and genomic DNA from culture cells was extracted using NucleoSpin Tissue extraction kits (Macherey-Nagel). Total RNA was isolated from leucocytes and mesenchymal cells using TRIzol(R) (Gibco BRL), treated with DNAse (Promega) and submitted to reverse transcription using Superscript II Reverse Transcriptase (Gibco BRL), according to manufacturer's protocol. Aliquots from DNAse treated RNAs were used for amplification of an intronic region of MLH1 gene as a control for DNA contamination (primers sequences on request).
###end p 24
###begin title 25
Mutation screening
###end title 25
###begin p 26
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 361 367 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 461 462 461 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 196 203 <span type="species:ncbi:9606">patient</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
###xml 483 491 <span type="species:ncbi:9606">patients</span>
Seven of the 23 patients included in the present report were previously studied by our group [3,9,21]. Pathogenic mutations were identified in six of these seven individuals (Table 1). Except for patient TCS17, for whom we did not have enough DNA, all the other 15 patients were submitted to molecular analysis to identify the pathogenic mutation. Screening of TCOF1 mutations by direct sequencing of genomic DNA was performed with primers described elsewhere [9]. Sequencing of the patients' cDNA was performed in identical conditions, but using primers that amplify only the coding region flanking the pathogenic mutation (see Additional file 1).
###end p 26
###begin p 27
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Pathogenic mutations of TCS patients analyzed for TCOF1 expression:
###end p 27
###begin title 28
Real Time PCR
###end title 28
###begin p 29
###xml 123 149 122 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SYBR Green PCR Master Mix </italic>
###xml 150 168 149 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Applied Biosystems</italic>
###xml 212 253 211 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABI Prism 7700 Sequence Detection System </italic>
###xml 254 272 253 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Applied Biosystems</italic>
###xml 368 386 367 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Applied Biosystems</italic>
###xml 424 425 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
###xml 526 536 525 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(-1/slope)</sup>
###xml 561 567 560 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 702 707 701 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 709 713 708 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BCRP</italic>
###xml 715 720 714 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HPRT1</italic>
###xml 726 730 725 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HMBS</italic>
###xml 784 795 783 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">geNorm VBA </italic>
###xml 815 830 814 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Microsoft Excel</italic>
###xml 1117 1119 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1260 1262 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
Real time quantitative PCR reactions were performed in duplicates with a final volume of 20 mul, using 12.5 ng of cDNA, 1x SYBR Green PCR Master Mix (Applied Biosystems) and 200 or 400 nM of each primer. We used ABI Prism 7700 Sequence Detection System (Applied Biosystems) with standard temperature protocol. Primers were designed with Primer Express software V.2.0 (Applied Biosystems; primers sequence in Additional file 1) and the amplification efficiency (E) of each primer was calculated according to the equation E = 10(-1/slope). The expression data of TCOF1 transcripts was determined by relative quantification in comparison to a pool of RNA from 10 controls. Four endogenous controls genes (GAPDH, BCRP, HPRT1, and HMBS), were used and their stability was verified through geNorm VBA applet designed for Microsoft Excel. This tool calculates the most stable reference genes from a set of tested candidate reference genes in a given sample panel, and calculates the gene expression normalization factor (NF) for each target sample based on the geometric mean of a user-defined number of housekeeping genes [22]. We calculated the NF for each sample based on the four endogenous controls and the expression data was calculated according to reference [23].
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Molecular characterization of the TCS patients
###end title 31
###begin p 32
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 574 575 574 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 618 625 <span type="species:ncbi:9606">patient</span>
Pathogenic mutations were identified in 13 of the novel 15 screened individuals: five had already been reported as pathogenic [9,21,24] and eight are herein described for the first time. These new mutations were considered pathogenic because they are a nonsense mutation (c.1609C>T), disrupt splicing (c.639+1G>A) or alter the reading frame (c.3853delC, c.1298delC, c.218_222insAACC, c.4344dupA, c.431delC). Mutation c.4375_4377delAAG (TCS18) causes an in phase deletion and excludes a Lysine residue from the protein C-terminal nucleolar localization signal [25]. In Table 1, mutation and tissue availability of each patient are depicted.
###end p 32
###begin title 33
RT-PCR in leucocytes
###end title 33
###begin p 34
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 213 219 213 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 420 428 420 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p = 0.39</italic>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
We first verified the range of TCOF1 transcript levels in leucocytes from 20 patients (Table 1) and 12 controls by real-time PCR, using as reference a pool of RNA from 10 controls. We observed a wide variation in TCOF1 expression in leucocytes from normal individuals (Figure 1; SD = 1.24). This wide variation of gene expression was also observed among TCS patients (Table 1; SD = 1.46), and was not correlated to age (p = 0.39; Two-tailed Pearson correlation regression).
###end p 34
###begin p 35
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Normalized <italic>TCOF1 </italic>expression levels in TCS patients (circles) and controls (squares)</bold>
###xml 85 88 85 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A) </bold>
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 230 233 222 225 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B) </bold>
###xml 233 239 225 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
Normalized TCOF1 expression levels in TCS patients (circles) and controls (squares). A) TCOF1 expression levels in leucocytes samples from patients (mean +/- SEM = 6.846 +/- 0.3278) and controls (mean +/- SEM = 8.093 +/- 0.3587). B) TCOF1 expression levels in mesenchymal cell samples from patients (mean +/- SEM = 0.9687 +/- 0.1122) and controls (mean +/- SEM = 1.414 +/- 0.09010). Mean expression value is represented by horizontal lines.
###end p 35
###begin p 36
###xml 134 140 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 213 223 205 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p = 0.0164</italic>
###xml 284 285 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 365 375 357 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p = 0.5828</italic>
###xml 426 432 418 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 583 593 575 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p = 0.0039</italic>
###xml 10 18 <span type="species:ncbi:9606">patients</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
###xml 494 502 <span type="species:ncbi:9606">patients</span>
Comparing patients (mean +/- SEM = 6.846 +/- 0.3278; N = 20) and controls (mean +/- SEM = 8.093 +/- 0.3587; N = 12), we observed that TCOF1 expression levels were significantly lower in patients than in controls (p = 0.0164; Two-tailed unpaired t test with Welch's correction; Figure 1), and the variances were not significantly different between these two groups (p = 0.5828, F test). TCS patients had approximately 18% less TCOF1 transcript levels than normal individuals. Excluding the four patients without an identified pathogenic mutation, we obtained similar results (~18.5%, p = 0.0039).
###end p 36
###begin title 37
RT-PCR in mesenchymal cells
###end title 37
###begin p 38
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S2">2</xref>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S3">3</xref>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
We also examined whether TCOF1 expression levels were decreased in mesenchymal cells. Flow cytometry results showed that most of the cells were positive for mesenchymal cell markers (>95%) and negative for endothelial and hematopoietic markers (see Additional files 2 and 3) in primary cell cultures from four patients and four controls.
###end p 38
###begin p 39
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 219 227 219 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p = 0.90</italic>
###xml 346 352 346 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 382 383 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 471 481 463 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p = 0.0213</italic>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 359 367 <span type="species:ncbi:9606">patients</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
We also observed a great variance in TCOF1 expression among mesenchymal cells from TCS patients (n = 4) and controls (n = 6), and the variances in these samples were also not significantly different between the groups (p = 0.90, F test). Although the number of tested individuals was smaller, we also detected a significantly lower expression of TCOF1 in TCS patients (~31%; Figure 2; patients mean +/- SEM = 0.9687 +/- 0.1122; controls mean +/- SEM = 1.414 +/- 0.09010; p = 0.0213; Two-tailed unpaired t test with Welch's correction). For this analysis, we also used as reference a pool of RNAs.
###end p 39
###begin p 40
###xml 0 115 0 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Genomic DNA (gDNA) and complementary DNA (cDNA) sequencing of mesenchymal stem cells samples from four TCS patients</bold>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
Genomic DNA (gDNA) and complementary DNA (cDNA) sequencing of mesenchymal stem cells samples from four TCS patients. The pathogenic mutation of TCS patients 16, 21, 22, and 23 are c.218_222insAACC (exon 3), c.4344dupA (exon 24), c.431delC (exon 5), and c.4218dupG (exon 23), respectively. gDNA was sequenced with intronic primers and cDNA with exonic primers. Observing all gDNA samples, we can assume that all analyzed individuals are heterozygous for the pathogenic mutation. Analyzing cDNA samples, we could detect the mutant allele expression in TCS 16 and 23; TCS 21 and 22 express only the wild-type allele. Note that even when the mutant allele is expressed (patients TCS16 and TCS23), the peak heights are lower.
###end p 40
###begin title 41
Mutant allele detection
###end title 41
###begin p 42
###xml 225 232 225 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus </italic>
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
In order to confirm the existence of NMD mechanism, we evaluated the expression of mutant alleles. We compared peak heights obtained through sequencing analysis of the nucleotides flanking the pathogenic mutation of the gDNA versus cDNA (Figure 2). We observed the expression of the mutant alleles in two patients (TCS16 and 23), but in patients TCS21 and 22 we could only detect the wild-type allele (Figure 2).
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 276 282 276 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
We present here the first quantification of TCOF1 transcripts in leucocytes and mesenchymal cells from TCS patients and controls. We observed a wide range of expression levels, with a variance that was very similar for individuals with or without a pathogenic mutation in the TCOF1 gene, and also independently from the tissue where the mRNA was obtained. The expression levels in leucocytes did not show dependence on age in TCS patients.
###end p 44
###begin p 45
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
We verified that the TCOF1 transcript levels were significantly reduced in patients as compared to controls in all the cell types studied. Our results demonstrated that the dosage compensation mechanism, proposed elsewhere [5], does not occur in adult leucocytes or mesenchymal cells, at least at the mRNA level. However, we cannot rule out the existence of post-translational regulatory mechanisms that assure the same amounts of treacle. Alternatively, the methods adopted for treacle quantification in the previous report were not able to detect a slight reduction in protein levels [5].
###end p 45
###begin p 46
###xml 276 282 276 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
Our findings are in accordance with the current hypothesis of haploinsufficiency for TCS, which predicts that the allele bearing a premature stop codon is degraded by NMD, and consequently patients have less gene product than normal individuals. In addition, the reduction of TCOF1 expression (18-31%) in adult cells of TCS patients as compared to controls is in accordance to the observed 5-25% reduction of transcript levels caused by NMD in the presence of premature stop codon mutations in mRNA molecules [26].
###end p 46
###begin p 47
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1</italic>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 759 760 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 976 978 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
In order to confirm if NMD mechanism was associated with the presence of null mutations in TCOF1, we evaluated if the mutant allele had reduced expression in cell culture from tissue samples of TCS patients. As we observed complete absence of mutant alleles in individuals TCS21 and 22, but partial expression in TCS23 (Figure 2), we considered that NMD was present, but with variable efficiency. Interestingly, TCS16 seemed to express both alleles in similar proportion. Although it had been described that NMD efficiency can vary according to the position of the premature stop codon [26], in these samples we did not observe any correlation between the location of the mutations at N or C-terminal and absence/reduction of mutant allele expression (Figure 2). It is possible that, in addition to NMD, other mechanisms of transcriptional regulation could be resulting in this observed differential allelic expression, such as epigenetic, environmental or stochastic events [27,28].
###end p 47
###begin title 48
Conclusions
###end title 48
###begin p 49
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1</italic>
###xml 322 328 322 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 480 486 480 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 629 637 <span type="species:ncbi:9606">patients</span>
We demonstrated that adult leucocytes and mesenchymal cells from TCS patients present significantly reduced levels of TCOF1. In addition, we showed that the mutant allele is much less abundant than the wild type and it might be in accordance with the hypothesis of mutant transcript degradation through NMD. Deficiency of TCOF1 in these cells opens a perspective to study the function of this gene in adulthood, particularly in adult stem cells. It will be important to verify if TCOF1 levels interfere in the renewal capacity of stem cells during bone regeneration process, as successful reconstruction of facial defects in TCS patients represents a challenge to plastic surgery.
###end p 49
###begin title 50
Abbreviations
###end title 50
###begin p 51
TCS: Treacher Collins syndrome; NMD: nonsense mediated mRNA decay; PTC: premature termination codon; NF: normalization factor.
###end p 51
###begin title 52
Competing interests
###end title 52
###begin p 53
The authors declare that they have no competing interests.
###end p 53
###begin title 54
Authors' contributions
###end title 54
###begin p 55
###xml 248 256 <span type="species:ncbi:9606">patients</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
CM carried out the leucocytes samples analysis, part of mutational screening and drafted the manuscript. CCO established and analyzed mesenchymal cell lines, carried out part of mutational screening. AS carried out part of mutational screening and patients recruitment. RM and AAC provided analytic and data assistance. TF and NA clinically analyzed TCS patients. MRPB provided analytical support and supervised the project. All authors have read and approved this final manuscript.
###end p 55
###begin title 56
Pre-publication history
###end title 56
###begin p 57
The pre-publication history for this paper can be accessed here:
###end p 57
###begin p 58

###end p 58
###begin title 59
Supplementary Material
###end title 59
###begin title 60
Additional file 1
###end title 60
###begin p 61
Primer sequences used in this report.
###end p 61
###begin p 62
Click here for file
###end p 62
###begin title 63
Additional file 2
###end title 63
###begin p 64
Percentage of positive cells for mesenchymal cell markers.
###end p 64
###begin p 65
Click here for file
###end p 65
###begin title 66
Additional file 3
###end title 66
###begin p 67
###xml 0 80 0 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flow cytometry analysis of mesenchymal cells from patients TCS16, 21, 22, and 23</bold>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Flow cytometry analysis of mesenchymal cells from patients TCS16, 21, 22, and 23. Values represent the mean percentage of all assessed cells positively stained by the indicated antigens (CD31, CD73 (SH4), (SH2) CD105) and analyzed by flow cytometry. Graphs show relative number of cells (events) versus fluorescence intensity. Unmarked cells (control) were used as negative controls in both non-conjugated and conjugated antibodies. Solid histograms (black) show marker expression; open histograms (grey) show no marker expression. Horizontal lines represent the range of positive cells interval. CD means cluster of differentiation.
###end p 67
###begin p 68
Click here for file
###end p 68
###begin title 69
Acknowledgements
###end title 69
###begin p 70
###xml 44 52 <span type="species:ncbi:9606">patients</span>
We would like to gratefully acknowledge the patients and their relatives. We also thank Constancia Gotto for secretarial assistance, Regina C. Mingroni Netto for some samples, and Diogo Meyer for helpful discussions and for carefully reading this manuscript. This work was supported by grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP/CEPID), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and Conselho Nacional de Pesquisa (CNPq).
###end p 70
###begin article-title 71
Branchial Arch and oral-Acral Disorders
###end article-title 71
###begin article-title 72
Treacher Collins syndrome: correlation between clinical and genetic linkage studies
###end article-title 72
###begin article-title 73
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
TCOF1 mutation database: novel mutation in the alternatively spliced exon 6A and update in mutation nomenclature
###end article-title 73
###begin article-title 74
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1</italic>
The Treacher Collins syndrome (TCOF1) gene product is involved in pre-rRNA methylation
###end article-title 74
###begin article-title 75
Characterization of the nucleolar gene product, treacle, in Treacher Collins syndrome
###end article-title 75
###begin article-title 76
Treacher Collins syndrome may result from insertions, deletions or splicing mutations, which introduce a termination codon into the gene
###end article-title 76
###begin article-title 77
The Mutational Spectrum in Treacher Collins Syndrome Reveals a Predominance of Mutations That Create a Premature-Termination Codon
###end article-title 77
###begin article-title 78
###xml 17 25 <span type="species:ncbi:9606">patients</span>
Genotyping in 46 patients with tentative diagnosis of Treacher Collins syndrome revealed unexpected phenotypic variation
###end article-title 78
###begin article-title 79
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
High mutation detection rate in TCOF1 among Treacher Collins syndrome patients reveals clustering of mutations in 16 novel pathogenic changes
###end article-title 79
###begin article-title 80
Positional cloning of a gene involved in the pathogenesis of Treacher Collins syndrome
###end article-title 80
###begin article-title 81
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tcof1 </italic>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1</italic>
###xml 94 100 <span type="species:ncbi:10090">murine</span>
###xml 178 183 <span type="species:ncbi:9606">human</span>
Sequence analysis, identification of evolutionary conserved motifs and expression analysis of murine Tcof1 provide further evidence for a potential function for the gene and its human homologue, TCOF1
###end article-title 81
###begin article-title 82
Increased levels of apoptosis in the prefusion neural folds underlie the craniofacial disorder, Treacher Collins
###end article-title 82
###begin article-title 83
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tcof1</italic>
Tcof1/Treacle is required for neural crest cell formation and proliferation deficiencies that cause craniofacial abnormalities
###end article-title 83
###begin article-title 84
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
Macular degeneration associated with a novel Treacher Collins TCOF1 mutation and evaluation of this mutation in age related macular degeneration
###end article-title 84
###begin article-title 85
bone lengthening: a serial histological study
###end article-title 85
###begin article-title 86
Long-term outcome study of bilateral mandibular distraction: a comparison of Treacher Collins and Nager syndromes to other types of micrognathia
###end article-title 86
###begin article-title 87
###xml 102 110 <span type="species:ncbi:9606">children</span>
Five year follow-up of mandibular distraction osteogenesis on the dentofacial structures of syndromic children
###end article-title 87
###begin article-title 88
###xml 115 123 <span type="species:ncbi:9606">Patients</span>
New Source of Muscle-Derived Stem Cells with Potential for Alveolar Bone Reconstruction in Cleft Lip and/or Palate Patients
###end article-title 88
###begin article-title 89
Apert p.Ser252Trp mutation in FGFR2 alters osteogenic potential and gene expression of cranial periosteal cells
###end article-title 89
###begin article-title 90
###xml 55 60 <span type="species:ncbi:9606">human</span>
A simple testing out procedure for extracting DNA from human nucleated cells
###end article-title 90
###begin article-title 91
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1 </italic>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Screening of TCOF1 in patients from different populations: confirmation of mutational hot spots and identification of a novel missense mutation that suggests an important functional domain in the protein treacle
###end article-title 91
###begin article-title 92
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
###end article-title 92
###begin article-title 93
A new mathematical model for quantification in real-time-RT-PCR
###end article-title 93
###begin article-title 94
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1</italic>
Identification of mutations in TCOF1: use of molecular analysis in the pre- and postnatal diagnosis of Treacher Collins syndrome
###end article-title 94
###begin article-title 95
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCOF1</italic>
The Treacher Collins syndrome (TCOF1) gene product, treacle, is targeted to the nucleolus by signals in the C-terminus
###end article-title 95
###begin article-title 96
Applying nonsense-metiated mRNA dacay research to the clinic: progress and challenges
###end article-title 96
###begin article-title 97
###xml 37 42 <span type="species:ncbi:9606">human</span>
Widespread monoallelic expression on human autosomes
###end article-title 97
###begin article-title 98
Stochasticity in gene expression: from theories to phenotypes
###end article-title 98

